Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FIGS, Inc. Class A Common Stock (NY: FIGS )

5.355 -0.095 (-1.74%)
Streaming Delayed Price Updated: 3:51 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about FIGS, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Consumer Discretionary Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
What 5 Analyst Ratings Have To Say About FIGS
Via Benzinga
Figs (FIGS) Q2 2023 Earnings Call Transcript
FIGS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
FIGS's Earnings Outlook
Via Benzinga
Expert Ratings for FIGS
Via Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Clothing Company FIGS' Solid Active Customer Base Boosts Q3 Profits & Guidance
Healthcare apparel and lifestyle brand FIGS, Inc (NYSE: FIGS) reported third-quarter FY23 sales growth of 11% year-on-year to $142.36 million,  
Via Benzinga
The Latest Analyst Ratings for FIGS
Via Benzinga
Figs (FIGS) Q1 2023 Earnings Call Transcript
FIGS earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Analyst Ratings for FIGS
Via Benzinga
What 8 Analyst Ratings Have To Say About FIGS
Via Benzinga
Figs (FIGS) Q3 2023 Earnings Call Transcript
FIGS earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
10 Consumer Discretionary Stocks Whale Activity In Today's Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session
Via Benzinga
10 Consumer Discretionary Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
U.S stocks closed higher on Friday, with the Dow Jones jumping more than 500 points during the session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
Figs Stock Is Down Nearly 90% From Its High. Time to Buy?
The medical apparel maker faces tough near-term headwinds. 
Via The Motley Fool
$5M Bet On FIGS? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
3 No-Brainer Stocks to Buy Right Now for Less than $25
Down between 86% to 92% from all-time highs, these stocks now trade at prices that make them worthy of a closer look. 
Via The Motley Fool
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at... 
Via Benzinga
The Good News From Salesforce
And we talk about people pulling back on spending on all those things that probably seemed essential in the earlier days of the pandemic. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Analyst Ratings for FIGS
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.